Background/Aims: The long-term effects of biocompatible peritoneal dialysis (PD) solution on residual renal function (RRF), inflammation, adipokines and metabolic acidosis are controversial. We evaluated the effects of biocompatible PD solution in continuous ambulatory PD (CAPD) patients for an additional 12-month period. Method: Among 91 incident patients who started CAPD with either biocompatible PD solution (Balance®, Fresenius; LS, n = 48) or conventional PD solution (CAPD/DPCA®, Fresenius; CS, n = 43), 63 patients, who were followed for 12 months, were enrolled and followed for an additional 12 months. Results: After 24 months of treatment, the glomerular filtration rate (GFR) of the LS group was twofold higher compared to the CS group (33.5 ± 30.7 vs. 16.3 ± 17.9 l/week/1.73 m2, respectively, p = 0.021). In a subgroup of patients with an initial GFR >2 ml/min/1.73 m2, the GFR of the LS group was significantly higher than the rate of the CS group after 24 months (43.7 ± 30.5 vs. 18.6 ± 19.0 l/week/1.73 m2, respectively, p = 0.042). Over a 24-month period, effluent cancer antigen-125 levels were significantly increased in the LS group compared to the CS group, while effluent interleukin-6 levels did not differ between the two groups. The serum tCO2 levels were consistently higher in the LS group compared to the CS group. Conclusions: We found that the effect of LS on preserving RRF may be maintained over a 24-month treatment period in CAPD patients, and LS use may have other benefits, such as the correction of metabolic acidosis.

Keywords:
End-stage renal disease, Glycation end products, Peritoneal dialysis, Creatinine clearance
1.
Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001;12:2158–2162.
2.
Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307–1320.
3.
Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD-2). Am J Kidney Dis 2003;41:1293–1302.
4.
Han SH, Ahn SV, Yun JY, Tranaeus A, Han DS: Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 2009;54:711–720.
5.
Justo P, Sanz AB, Egido J, Ortiz A: 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005;54:2424–2429.
6.
Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM: Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008;73:200–206.
7.
Kim S, Oh J, Chung W, Ahn C, Kim SG, Oh KH: Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009;24:2899–2908.
8.
Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, Law MC, Li PK: Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products – a 1-year randomized control trial. Nephrol Dial Transplant 2007;22:552–559.
9.
Haag-Weber M, Kramer R, Haake R, Islam MS, Prischl F, Haug U, Nabut JL, Deppisch R: Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010;25:2288–2296.
10.
Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408–418.
11.
Park SH, Do JY, Kim YH, Lee HY, Kim BS, Shin SK, Kim HC, Chang YK, Yang JO, Chung HC, Kim CD, Lee WK, Kim JY, Kim YL: Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study. Nephrol Dial Transplant 2012;27:1191–1199.
12.
Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Garcia-Naveiro R, Isidro ML, Villaverde P, Garcia-Buela J: Acute plasma ghrelin and leptin responses to oral feeding or intraperitoneal hypertonic glucose-based dialysate in patients with chronic renal failure. Kidney Int 2005;68:2877–2885.
13.
Furuya R, Odamaki M, Kumagai H, Hishida A: Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2006;21:494–498.
14.
Rodriguez-Carmona A, Perez-Fontan M, Guitian A, Peteiro J, Garcia-Falcon T, Lopez-Muniz A, Garcia-Buela J, Cordido F: Effect of low GDP bicarbonate lactate-buffered peritoneal dialysis solutions on plasma levels of adipokines and gut appetite-regulatory peptides. A randomized crossover study. Nephrol Dial Transplant 2012;27:369–374.
15.
Johnson DW, Clarke M, Wilson V, Woods F, Brown FG: Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function. BMC Nephrol 2010;11:25.
16.
Davies SJ, Russell L, Bryan J, Phillips L, Russell GI: Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. Am J Kidney Dis 1995;26:353–361.
17.
Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 1989;5:303–312.
18.
Watson PE, Watson ID, Batt RD: Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980;33:27–39.
19.
Smit W, van Dijk P, Langedijk MJ, Schouten N, van den Berg N, Struijk DG, Krediet RT: Peritoneal function and assessment of reference values using a 3.86% glucose solution. Perit Dial Int 2003;23:440–449.
20.
Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L: Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005;25:107–131.
21.
Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002;13:1733–1739.
22.
Srivastava S, Hildebrand S, Fan SL: Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival. Kidney Int 2011;80:986–991.
23.
Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan SH, Voss D: Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012;23:1097–1107.
24.
Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG: Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000;20:429–438.
25.
Sung SA, Hwang YH, Kim S, Kim SG, Oh J, Chung W, Lee SY, Ahn C, Oh KH: Loss of residual renal function was not associated with glycemic control in patients on peritoneal dialysis. Perit Dial Int 2011;31:154–159.
26.
Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N: Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001;21(suppl 3):S102–S107.
27.
Molitoris BA, Sandoval RM: Kidney endothelial dysfunction: ischemia, localized infections and sepsis. Contrib Nephrol. Basel, Karger, 2011, vol 174, pp 108–118.
28.
Han SH, Lee SC, Kang EW, Park JK, Yoon HS, Yoo TH, Choi KH, Han DS, Kang SW: Reduced residual renal function is associated with endothelial dysfunction in patients receiving peritoneal dialysis. Perit Dial Int 2012;32:149–158.
29.
Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J: Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998;54:1731–1738.
30.
Park MS, Kim JK, Holmes C, Weiss MF: Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation. Perit Dial Int 2000;20(suppl 5):S33–S38.
31.
Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, Wesson DE: Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010;77:617–623.
32.
Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE: Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010;78:303–309.
33.
De Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM: Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009;20:2075–2084.
34.
Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, Ahlmen J, Larsson R, Ingman B, Simonsen O, van Hamersvelt HW, Johansson AC, Hylander B, Mayr M, Nilsson PH, Andersson PO, De los Rios T: Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 2009;29:647–655.
35.
Montenegro J, Saracho RM, Martinez IM, Munoz RI, Ocharan JJ, Valladares E: Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006;26:89–94.
36.
Konings CJ, Kooman JP, Gladziwa U, van der Sande FM, Leunissen KM: A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005;67:1190–1191.
37.
Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, Gerlag PG, Hoorntje SJ, Wolters J, van der Sande FM, Leunissen KM: Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003;63:1556–1563.
38.
Davies SJ: Preserving residual renal function in peritoneal dialysis: volume or biocompatibility? Nephrol Dial Transplant 2009;24:2620–2622.
39.
Merabet E, Dagogo-Jack S, Coyne DW, Klein S, Santiago JV, Hmiel SP, Landt M: Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1997;82:847–850.
40.
Nanayakkara PW, Le Poole CY, Fouque D, van Guldener C, Stehouwer CD, Smulders YM, van Ittersum FJ, Siegert CE, Drai J, Kostense PJ, ter Wee PM: Plasma adiponectin concentration has an inverse and a non-linear association with estimated glomerular filtration rate in patients with K/DOQI stage 3–5 chronic kidney disease. Clin Nephrol 2009;72:21–30.
41.
Duranay M, Kanbay M, Turgut F, Altay M, Akcay A: Comparison of incidence of peritonitis between peritoneal dialysis solution types. Nephron Clin Pract 2007;106:C57–C60.
42.
Johnson DW, Mudge DW, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, Hollett P: Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 2003;23:276–283.
43.
Han SH, Lee SC, Ahn SV, Lee JE, Kim DK, Lee TH, Moon SJ, Kim BS, Kang SW, Choi KH, Lee HY, Han DS: Reduced residual renal function is a risk of peritonitis in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 2007;22:2653–2658.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.